Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PACB – Pacific Biosciences of California, Inc.

Pacific Biosciences of Californ
PACB
$1.29
Name : Pacific Biosciences of Californ
Sector : Healthcare
Industry: Medical Devices
Mark. Cap: $387,109,632.00
EPSttm : -2.74
finviz dynamic chart for PACB
Pacific Biosciences of Californ
$1.29
0.00%
$0.0000

Float Short %

15.01

Margin Of Safety %

Put/Call OI Ratio

0.31

EPS Next Q Diff

EPS Last/This Y

0.49

EPS This/Next Y

0.12

Price

1.29

Target Price

1.96

Analyst Recom

2.21

Performance Q

4.03

Relative Volume

1.52

Beta

2.15

Ticker: PACB




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02PACB0.99310.310.10146975
2025-06-03PACB1.060.310.28147556
2025-06-04PACB1.020.301.16148404
2025-06-05PACB1.010.310.02149064
2025-06-06PACB1.130.310.02149061
2025-06-09PACB1.2050.291.60155754
2025-06-10PACB1.1650.300.20156582
2025-06-11PACB1.170.300.00156663
2025-06-12PACB1.180.300.06156828
2025-06-13PACB1.210.300.04156407
2025-06-16PACB1.3850.300.39156258
2025-06-17PACB1.3050.300.20155297
2025-06-18PACB1.3050.300.91155870
2025-06-20PACB1.2650.300.40155483
2025-06-23PACB1.1850.310.1092601
2025-06-24PACB1.1950.310.0192771
2025-06-25PACB1.2150.310.0093009
2025-06-26PACB1.2850.310.6193422
2025-06-27PACB1.2950.310.9893451
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02PACB0.9917.7260.9-0.63
2025-06-03PACB1.0517.7254.8-0.63
2025-06-04PACB1.0117.7272.4-0.63
2025-06-05PACB1.0017.7270.7-0.63
2025-06-06PACB1.1317.7242.9-0.64
2025-06-09PACB1.2017.0255.7-0.64
2025-06-10PACB1.1617.0271.9-0.64
2025-06-11PACB1.1617.0264.7-0.64
2025-06-12PACB1.1817.0262.3-0.64
2025-06-13PACB1.2117.0260.7-0.64
2025-06-16PACB1.3917.0235.3-0.64
2025-06-17PACB1.3017.0277.4-0.64
2025-06-18PACB1.3117.0264.0-0.64
2025-06-20PACB1.2717.0271.6-0.64
2025-06-23PACB1.1817.0278.0-0.64
2025-06-24PACB1.2017.0264.7-0.64
2025-06-25PACB1.2117.0264.0-0.64
2025-06-26PACB1.2917.0252.8-0.64
2025-06-27PACB1.2917.0264.8-0.64
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02PACB-1.23-12.6821.56
2025-06-03PACB-1.23-12.6821.56
2025-06-04PACB-1.23-12.6821.56
2025-06-05PACB-1.23-12.6821.56
2025-06-06PACB-1.23-12.6821.56
2025-06-09PACB-1.23-12.6721.56
2025-06-10PACB-1.23-12.6721.56
2025-06-11PACB-1.23-12.6719.69
2025-06-12PACB-1.23-12.6719.69
2025-06-13PACB-1.23-12.6719.69
2025-06-16PACB-1.23-12.7019.69
2025-06-18PACB-1.23-12.7019.69
2025-06-20PACB-1.23-12.7019.69
2025-06-23PACB-1.23-12.7019.69
2025-06-24PACB-1.23-12.7019.69
2025-06-25PACB-1.23-12.7019.69
2025-06-26PACB-1.23-12.7015.01
2025-06-27PACB-1.23-12.7015.01
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

-0.15

Avg. EPS Est. Current Quarter

-0.17

Avg. EPS Est. Next Quarter

-0.15

Insider Transactions

-1.23

Institutional Transactions

-12.7

Beta

2.15

Average Sales Estimate Current Quarter

36

Average Sales Estimate Next Quarter

39

Fair Value

Quality Score

18

Growth Score

41

Sentiment Score

44

Actual DrawDown %

97.6

Max Drawdown 5-Year %

-98.2

Target Price

1.96

P/E

Forward P/E

PEG

P/S

2.54

P/B

4.22

P/Free Cash Flow

EPS

-2.77

Average EPS Est. Cur. Y​

-0.64

EPS Next Y. (Est.)

-0.52

Target Price Estimates Raised

Target Price Estimates Lowered

1

Profit Margin

-430.93

Relative Volume

1.52

Return on Equity vs Sector %

-741.7

Return on Equity vs Industry %

-736.2

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

264.8
Pacific Biosciences of Californ
Sector: Healthcare
Industry: Medical Devices
Employees: 575
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, Sequel, Sequel II, and Sequel IIe instruments which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. It serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
stock quote shares PACB – Pacific Biosciences of California, Inc. Stock Price stock today
news today PACB – Pacific Biosciences of California, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PACB – Pacific Biosciences of California, Inc. yahoo finance google finance
stock history PACB – Pacific Biosciences of California, Inc. invest stock market
stock prices PACB premarket after hours
ticker PACB fair value insiders trading